Songdo's state-built bio lab hub will cost about 3.6 billion won per startup tenant

Spread across the 60 startups expected to move in, the budget comes to about 3.6 billion won a tenant ^[3]. Per square meter of floor space it is roughly 10.7 million won ^[4]. Both figures include construction, and the project team calls the budget tight for that reason ^[9]. Minister Lee So-young made the same point by comparison, saying a single quantum computer can cost as much as 100 billion won ^[10]. One such machine would take about 46% of the entire budget ^[5]. Tenants will instead get time on the 127-qubit IBM machine Yonsei already owns, the only one held by an institution in Korea ^[6].

Who pays matters more to the deal-flow question than the total does. The central government and Incheon put in 188.4 billion won between them, about 87% ^[2]. Yonsei adds 20.8 billion won and the private sector 8.1 billion won, about 3.7% [c8, d1]. The plan as reported pays for space, equipment and introductions to large companies, and it does not describe a fund that takes stakes in tenants [c4, c5, c7].

Lee's case is about location. "Songdo is a production base for Korea's bio industry, but it is still centered on large companies. If venture startups developing new drugs also move in, the ecosystem will become stronger and generate far more value," she said after the groundbreaking ceremony at Yonsei University's International Campus ^[1]. Lee Jae-sun, who heads the project team, said the real value in bio comes from developing new drugs, citing Moderna's rapid growth on its COVID-19 vaccine ^[12]. Songdo Severance Hospital is being built near the site ^[14].

If Celltrion, Samsung Biologics and SK bioscience treat 60 new neighbors as a scouting list, licensing and early funding for Korean drug startups could start to gather in Songdo by the time the building opens [c7, c3]. If tenants come mainly for the equipment, the hub becomes a well-stocked shared lab and the fundraising happens wherever the investors are. Kang Dong-young, a team leader on the project, said it is extremely difficult for startups to equip their own labs from the outset, and that many companies are already asking to move in for that reason ^[11]. The instrument count is due to rise roughly 22-fold by 2028 ^[6].

I think the second outcome fits the published evidence better. Demand for space shows up in the eight-company pilot and in the inquiries Kang described [c4, c11]. Demand from investors does not show up yet: private money is the smallest line in the budget, and the tie to the big producers is a ministry plan [c8, c7]. The counter-case is fair. A building that is still a construction site cannot show deal flow yet, and any pull from nearby production plants would appear later, when tenants reach clinical trials. The view is wrong if one of the three producers, or a private fund, puts money or contracts into the hub or its tenants before the building opens in 2028 ^[3].